Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2021
Subsidiary's RMB 164 million in improperly recorded expenses draws maximum penalty from Ministry of Finance
In 2020 the Ministry of Finance conducted accounting information quality inspections of 77 pharmaceutical companies and announced the results in 2021: China Resources Sanjiu's wholly owned subsidiary Shenzhen China Resources Sanjiu Pharmaceutical Trading Co., Ltd. in 2018 had improperly recorded expenses for video production, logistics supervision, meetings and research, involving about RMB 164 million, and was fined RMB 50,000 at the maximum. Hengrui Pharmaceuticals, Shanghai Pharmaceuticals, Buchang Pharmaceuticals and 19 other drug companies were also on the "blacklist." Media widely questioned the commercial bribery risks behind huge "promotion fees," pushing compliance rectification in the pharmaceutical industry.
2015
China Resources Sanjiu subsidiary's Shuxuening Injection fails spot check; recalled and production and sales suspended
Securities Times reported that a spot check on February 17, 2015 found two batches of Shuxuening Injection from China Resources Gaoke failed. The company recalled the relevant batches and proactively expanded the recall, suspended production and sales of the product, and carried out risk assessment and rectification. The company said at the time it had not received reports of serious adverse reactions. Progress: the company announcement confirmed the recall and suspension of production and sales. Subjects involved: Beijing China Resources Gaoke Natural Medicine Co., Ltd. and China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Scope: the Shuxuening product incident at subsidiary Beijing China Resources Gaoke Natural Medicine.